Online inquiry

IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14327MR)

This product GTTS-WQ14327MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFL7 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016215.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51162
UniProt ID Q9UHF1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14327MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3307MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ4442MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ12436MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ7181MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ13958MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ1649MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACT-017
GTTS-WQ13091MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ979MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-368
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW